Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 9Colorectal Neoplasms 7Rectal Neoplasms 5Colorectal Cancer Metastatic 5Ovarian Neoplasms 4Neoplasms 4Lung Neoplasms 3Colonic Neoplasms 3Uveal Melanoma 2Melanoma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neurofibromatosis 2 1Myeloproliferative Disorders 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Macular Degeneration 1

Interventions

Fluorouracil 34Cisplatin 34Radiotherapy 30Oxaliplatin 30Paclitaxel 22pembrolizumab 20Irinotecan 20Docetaxel 20Leucovorin 19Capecitabine 16Cetuximab 11Carboplatin 11Bevacizumab 11Radiation 10Surgical Procedures, Operative 9Trastuzumab 8Panitumumab 6Epirubicin 6Neoadjuvant Therapy 5Esophagectomy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4tisotumab vedotin 3durvalumab 3Sunitinib 3Microarray Analysis 3Immunohistochemistry 3Gene Expression Profiling 3Gemcitabine 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Neoplasms × aflibercept × Clear all
NCT01747551 2020-02-10

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
64 enrolled 11 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡